Targeting HDAC And PI3K Inhibits MYC-Driven Medulloblastoma Growth.

abstract：:The DREAM challenge is a community effort to assess current capabilities in systems biology. Two recent challenges focus on cancer cell drug sensitivity and drug synergism, and highlight strengths and weaknesses of current approaches. ...

journal_title：Cancer discovery

authors： Altman RB

更新日期：2015-03-01 00:00:00

abstract：:New research shows immunotherapy can cause lethal inflammation in both young and aged mice that are obese. Restricting calories in aged mice protected them from toxicity, and giving young obese mice a drug for autoimmune disease prevented the fatal reactions. ...

journal_title：Cancer discovery

authors：

更新日期：2015-01-01 00:00:00

abstract：:Epigenetic regulators, when genomically altered, may become driver oncogenes that mediate otherwise unexplained pro-oncogenic changes lacking a clear genetic stimulus, such as activation of the WNT/β-catenin pathway in melanoma. This study identifies previously unrecognized recurrent activating mutations in the G9a hi...

journal_title：Cancer discovery

authors： Kato S,Weng QY,Insco ML,Chen KY,Muralidhar S,Pozniak J,Diaz JMS,Drier Y,Nguyen N,Lo JA,van Rooijen E,Kemeny LV,Zhan Y,Feng Y,Silkworth W,Powell CT,Liau BB,Xiong Y,Jin J,Newton-Bishop J,Zon LI,Bernstein BE,Fish

更新日期：2020-07-01 00:00:00

abstract：:YY1 preferentially occupies active enhancers and promoters and forms dimers to promote DNA looping. ...

journal_title：Cancer discovery

authors：

更新日期：2018-02-01 00:00:00

abstract：:We performed cytosine methylation sequencing on genetically diverse patients with acute myeloid leukemia (AML) and found leukemic DNA methylation patterning is primarily driven by nonpromoter regulatory elements and CpG shores. Enhancers displayed stronger differential methylation than promoters, consisting predominan...

journal_title：Cancer discovery

authors： Glass JL,Hassane D,Wouters BJ,Kunimoto H,Avellino R,Garrett-Bakelman FE,Guryanova OA,Bowman R,Redlich S,Intlekofer AM,Meydan C,Qin T,Fall M,Alonso A,Guzman ML,Valk PJM,Thompson CB,Levine R,Elemento O,Delwel R,Meln

更新日期：2017-08-01 00:00:00

abstract：:Effective targeted therapeutics for squamous cell carcinoma (SCC) are lacking. Here, we uncover Mcl-1 as a dominant and tissue-specific survival factor in SCC, providing a roadmap for a new therapeutic approach. Treatment with the histone deacetylase (HDAC) inhibitor vorinostat regulates Bcl-2 family member expression...

journal_title：Cancer discovery

authors： He L,Torres-Lockhart K,Forster N,Ramakrishnan S,Greninger P,Garnett MJ,McDermott U,Rothenberg SM,Benes CH,Ellisen LW

更新日期：2013-03-01 00:00:00

abstract：:In this issue of Cancer Discovery, Dominguez and colleagues identify diacylglycerol kinase alpha (DGKα), an enzyme that converts the membrane lipid diacylglycerol to phosphatidic acid, as a central node upstream of mTOR and other oncogenic pathways. Importantly, targeting DGKα causes apoptosis in cancer cells and tumo...

journal_title：Cancer discovery

authors： Bhat KP,Aldape K

更新日期：2013-07-01 00:00:00

abstract：:53BP1 integrates pRB activity with the DNA damage response by binding to methylated K810. ...

journal_title：Cancer discovery

authors：

更新日期：2014-09-01 00:00:00

abstract：:A new study by Juergens and colleagues provides the first successful example of a combined epigenetic therapy capable of achieving results similar to those of conventional chemotherapy in refractory metastatic non-small cell lung cancer. Furthermore, the authors describe interesting blood-based DNA methylation biomark...

journal_title：Cancer discovery

authors： Rodríguez-Paredes M,Esteller M

更新日期：2011-12-01 00:00:00

abstract：:Adding a PI3K inhibitor to anti-estrogen receptor therapy may be a viable treatment option for women with advanced hormone receptor-positive breast cancer that becomes resistant to endocrine therapy, according to findings from the phase III BELLE-2 trial, presented at the 2015 San Antonio Breast Cancer Symposium. ...

journal_title：Cancer discovery

authors：

更新日期：2016-02-01 00:00:00

abstract：:Metastasizing tumor cells lose expression of the tumor suppressor PTEN at a much higher rate when they enter the brain compared to other organs, suggesting that the brain's unique microenvironment may prime metastatic cells for aggressive growth, a recent study reports. The findings may have implications for developin...

journal_title：Cancer discovery

authors：

更新日期：2016-01-01 00:00:00

abstract：:Pemigatinib was effective in patients with cholangiocarcinomas with FGFR2 fusions or rearrangements. ...

journal_title：Cancer discovery

authors：

更新日期：2020-05-01 00:00:00

abstract：:The PD-1 inhibitor pembrolizumab in combination with chemotherapy may be an effective therapy for patients with newly diagnosed advanced non-squamous non-small cell lung cancer. In a clinical trial, patients who received the combination had an estimated 12-month overall survival rate of 69.2%, compared with 49.4% in p...

journal_title：Cancer discovery

authors：

更新日期：2018-06-01 00:00:00

abstract：:With advances in technology and bioinformatics, we are now positioned to view and manage cancer through an evolutionary lens. This perspective is critical as our appreciation for the role of tumor heterogeneity, tumor immune compartment, and tumor microenvironment on cancer pathogenesis and evolution grows. Here, we e...

journal_title：Cancer discovery

authors： McCoach CE,Bivona TG

更新日期：2019-05-01 00:00:00

abstract：:Kidney cancer is not a single disease but represents several distinct types of cancer that have defining histologies and genetic alterations and that follow different clinical courses and have different responses to therapy. Mutation of genes associated with kidney cancer, such as VHL, FLCN, TFE3, FH, or SDHB, dysregu...

journal_title：Cancer discovery

authors： Linehan WM,Schmidt LS,Crooks DR,Wei D,Srinivasan R,Lang M,Ricketts CJ

更新日期：2019-08-01 00:00:00

abstract：:The FDA approved 22 novel drugs in 2016, down from 45 in 2015. Four of the new therapies are for cancer treatment, and two are for cancer diagnosis. ...

journal_title：Cancer discovery

authors：

更新日期：2017-02-01 00:00:00

abstract：:By law, the U.S. Food and Drug Administration has the authority, through its Center for Tobacco Products, to regulate the manufacture, marketing, and distribution of tobacco products. Its director, Mitchell Zeller, JD, talks about how the center, though its research, public education, and enforcement activities, aims ...

journal_title：Cancer discovery

authors： Zeller M,Rose S

更新日期：2014-01-01 00:00:00

abstract：:According to results from ENZAMET, a global phase III trial, adding enzalutamide to standard treatment for men with metastatic hormone-sensitive prostate cancer is superior in prolonging survival compared with older nonsteroidal antiandrogen drugs. ...

journal_title：Cancer discovery

authors：

更新日期：2019-08-01 00:00:00

abstract：:A new study of zebrafish may explain why only certain skin cells grow into tumors. Besides melanoma-promoting mutations, these cells express key neural crest genes, such as crestin and sox10, that induce regression to an embryonic state. They also bear epigenetic changes that might amplify expression of these genes. ...

journal_title：Cancer discovery

authors： Leslie M

更新日期：2016-04-01 00:00:00

abstract：:In a first-in-human trial of an anti-CD22 chimeric antigen receptor T-cell therapy in children and young adults with relapsed and refractory acute lymphocytic leukemia, researchers found that the immunotherapeutic approach was not only feasible and safe, but also effective, leading to remissions in most patients. Infu...

journal_title：Cancer discovery

authors：

更新日期：2017-02-01 00:00:00

abstract：:According to findings of a study in the Journal of the National Cancer Institute, people with a single-nucleotide polymorphism on chromosome 8q24 who regularly use aspirin can cut their risk of colorectal cancer by about half. ...

journal_title：Cancer discovery

authors：

更新日期：2014-03-01 00:00:00

abstract：:The TIGIT inhibitor tiragolumab, alone or in combination with the PD-L1 inhibitor atezolizumab, may be effective against solid cancers. In phase I and II trials, the agent achieved statistically significant results in multiple solid malignancies-most notably non-small cell lung cancer. ...

journal_title：Cancer discovery

authors：

更新日期：2020-08-01 00:00:00

abstract：:Presenting data on 50 of 55 patients with advanced TRK fusion-positive tumors, researchers reported that 76% of patients responded to the selective pan-TRK inhibitor larotrectinib, and 12% of patients experienced complete responses; 93% of responders remain on therapy. The targeted therapy was well tolerated, with jus...

journal_title：Cancer discovery

authors：

更新日期：2017-08-01 00:00:00

abstract：:MYC is implicated in the development and progression of pancreatic cancer, yet the precise level of MYC deregulation required to contribute to tumor development has been difficult to define. We used modestly elevated expression of human MYC, driven from the Rosa26 locus, to investigate the pancreatic phenotypes arisin...

journal_title：Cancer discovery

authors： Muthalagu N,Monteverde T,Raffo-Iraolagoitia X,Wiesheu R,Whyte D,Hedley A,Laing S,Kruspig B,Upstill-Goddard R,Shaw R,Neidler S,Rink C,Karim SA,Gyuraszova K,Nixon C,Clark W,Biankin AV,Carlin LM,Coffelt SB,Sansom OJ,

更新日期：2020-06-01 00:00:00

abstract：:Electronic cigarettes (e-cigarettes) may be an effective tool for smoking cessation. In a randomized trial, researchers found that 18% of those assigned to use e-cigarettes were smoke-free after a year, compared with 9.9% of those assigned to nicotine replacement therapies such as patches and gum. However, those in th...

journal_title：Cancer discovery

authors：

更新日期：2019-04-01 00:00:00

abstract：:Ubiquitin-specific protease 2a, a deubiquitinating enzyme, elevates MYC levels in prostate cancer cells via its stabilization of MDM2, undermining p53 regulation of microRNAs that target MYC mRNA. ...

journal_title：Cancer discovery

authors： Nelson WG,De Marzo AM,Yegnasubramanian S

更新日期：2012-03-01 00:00:00

abstract：:The appearance of a mutant androgen receptor, AR(F876L), in prostate cancer cells chronically exposed to enzalutamide or ARN-509 promotes a switch from antagonist to agonist receptor function, undermining the potential long-term effectiveness of these second-generation antiandrogen drugs. ...

journal_title：Cancer discovery

authors： Nelson WG,Yegnasubramanian S

更新日期：2013-09-01 00:00:00

abstract：:Spliceosome inhibitors induced mRNA missplicing, retaining introns that formed double-stranded RNA. ...

journal_title：Cancer discovery

authors：

更新日期：2021-01-22 00:00:00

abstract：:CD14+CD16-HLA-DRhi monocyte frequency was linked to response to anti-PD-1 in patients with melanoma. ...

journal_title：Cancer discovery

authors：

更新日期：2018-03-01 00:00:00

abstract：:Notch activation, which is associated with basal-like breast cancer (BLBC), normally directs tissue patterning, suggesting that it may shape the tumor microenvironment. Here, we show that Notch in tumor cells regulates the expression of two powerful proinflammatory cytokines, IL1β and CCL2, and the recruitment of tumo...

journal_title：Cancer discovery

authors： Shen Q,Cohen B,Zheng W,Rahbar R,Martin B,Murakami K,Lamorte S,Thompson P,Berman H,Zúñiga-Pflücker JC,Ohashi PS,Reedijk M

更新日期：2017-11-01 00:00:00